Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.37 |
| ▸ | LPL | P06858 | 3/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PTGIR | P43119 | 5/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443872 | 0.81 | LIPG (0.57) | LIPGLPLP4HBNPSR1F2 | |
| SCHEMBL276100 | 0.80 | CXCR2 (0.34) | ROCK1LIPGLPLF2F11 | |
| SCHEMBL26969009 | 0.76 | LPL (0.38) | LIPGLPLJAK2BTK | |
| SCHEMBL25274580 | 0.75 | LPL (0.33) | LIPGLPLESR1ESR2F2 | |
| SCHEMBL29536788 | 0.75 | LPL (0.33) | LIPGLPLESR1ESR2F2 | |
| SCHEMBL1129705 | 0.75 | NPC1 (0.44) | ROCK1P4HBNPSR1 | |
| SCHEMBL2092753 | 0.74 | PTGIR (0.49) | ESR1ESR2PTGIRPTGDRNPSR1 | |
| SCHEMBL1130939 | 0.74 | LMNA (0.45) | ROCK1LIPGLPLP4HBF2 | |
| SCHEMBL29528340 | 0.74 | LMNA (0.45) | ROCK1LIPGLPLP4HBF2 | |
| SCHEMBL24745880 | 0.73 | RXRA (0.33) | ROCK1LIPGLPLLIPERXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2406258-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Cellzome Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011107585-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | ROCK1 2340/4885LIPG 4309/4885LPL 4498/4885 |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | MTOR, EIF4E, EIF4A1 | ROCK1 2595/4885LIPG 4470/4885LPL 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.